

Daniela Pugliese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1403887/publications.pdf>

Version: 2024-02-01

62
papers

1,582
citations

257101

24
h-index

329751

37
g-index

62
all docs

62
docs citations

62
times ranked

2414
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: An open-label pilot study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e623-e629.	0.6	85
2	Management of perianal fistulas in Crohn's disease: An up-to-date review. <i>World Journal of Gastroenterology</i> , 2015, 21, 1394.	1.4	82
3	Anti-TNF- α therapy for ulcerative colitis: current status and prospects for the future. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 223-233.	1.3	78
4	Adalimumab in active ulcerative colitis: A real-life observational study. <i>Digestive and Liver Disease</i> , 2013, 45, 738-743.	0.4	72
5	Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor- α agents. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 113-119.	0.6	68
6	Anti-TNF- α therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1435-1444.	1.0	66
7	Infliximab in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1065-1072.	0.9	66
8	Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor- α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. <i>Digestive and Liver Disease</i> , 2014, 46, 974-979.	0.4	64
9	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease: A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2442-2451.	0.9	56
10	Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1368-1374.	0.9	55
11	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 568-579.	0.9	51
12	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1079-1088.	0.6	50
13	Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2886-2893.	0.9	42
14	Frontiers in Drug Research and Development for Inflammatory Bowel Disease. <i>Frontiers in Pharmacology</i> , 2017, 8, 400.	1.6	40
15	Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. <i>United European Gastroenterology Journal</i> , 2020, 8, 775-781.	1.6	40
16	Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 335-339.	0.6	37
17	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD real AGED study. <i>Digestive and Liver Disease</i> , 2017, 49, 17-23.	0.4	35
18	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1306-1314.	0.9	35

#	ARTICLE	IF	CITATIONS
19	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110066.	1.4	34
20	Combination therapy in inflammatory bowel disease “ from traditional immunosuppressors towards the new paradigm of dual targeted therapy. <i>Autoimmunity Reviews</i> , 2021, 20, 102832.	2.5	34
21	FOXP3 ⁺ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF ± Agents. <i>BioMed Research International</i> , 2013, 2013, 1-10.	0.9	31
22	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 1189-1197.	1.6	31
23	Update on the management of inflammatory bowel disease: specific role of adalimumab. <i>Clinical and Experimental Gastroenterology</i> , 2011, 4, 163.	1.0	29
24	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. <i>Digestive and Liver Disease</i> , 2019, 51, 972-977.	0.4	25
25	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 95-109.	1.9	25
26	The role of multimodal treatment in Crohn’s disease patients with perianal fistula: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 941-950.	1.9	24
27	Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 853.	1.0	22
28	Anti-TNF alpha in the treatment of ulcerative colitis: A valid approach for organ-sparing or an expensive option to delay surgery?. <i>World Journal of Gastroenterology</i> , 2014, 20, 4839.	1.4	22
29	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.4	22
30	Ileal Crohn’s disease: CEUS determination of activity. <i>Abdominal Imaging</i> , 2012, 37, 359-368.	2.0	21
31	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2019, 51, 510-515.	0.4	18
32	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	1.3	16
33	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020, 8, 1228-1235.	1.6	16
34	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. <i>RMD Open</i> , 2018, 4, e000667.	1.8	15
35	Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 751-759.	1.3	14
36	Late-onset Crohn’s disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease “AGED” study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1361-1369.	0.8	14

#	ARTICLE	IF	CITATIONS
37	Therapeutic drug monitoring of anti-TNF- α agents in inflammatory bowel diseases. Expert Opinion on Biological Therapy, 2015, 15, 1107-1117.	1.4	13
38	Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. Journal of Gastrointestinal and Liver Diseases, 2013, 22, 21-5.	0.5	13
39	Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach. Italian Journal of Pediatrics, 2021, 47, 18.	1.0	12
40	Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United European Gastroenterology Journal, 2021, 9, 507-516.	1.6	11
41	Comment on: Emergence of severe spondyloarthropathy-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology, 2019, 58, 1113-1115.	0.9	9
42	Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. Drug Design, Development and Therapy, 2013, 7, 289.	2.0	8
43	Two-year effectiveness and safety of golimumab in ulcerative colitis: An IGBD study. United European Gastroenterology Journal, 2021, 9, 102-109.	1.6	8
44	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine, 2021, 10, 2914.	1.0	8
45	Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. Gastroenterology Research and Practice, 2018, 2018, 1-7.	0.7	7
46	Are we choosing wisely for inflammatory bowel disease care? The IGBD choosing wisely campaign. Digestive and Liver Disease, 2020, 52, 44-50.	0.4	7
47	Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211022.	1.4	7
48	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. Inflammatory Bowel Diseases, 2020, 26, e134-e136.	0.9	6
49	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 387.	0.6	6
50	Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Current Medical Research and Opinion, 2020, 36, 7-8.	0.9	5
51	Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis. United European Gastroenterology Journal, 2020, 8, 11-12.	1.6	5
52	The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When "non-urgent" does not mean "deferrable". Digestive and Liver Disease, 2020, 52, 1238-1240.	0.4	4
53	Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. Minerva Gastroenterologica E Dietologica, 2020, 65, 280-290.	2.2	4
54	Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug, Healthcare and Patient Safety, 2016, 8, 1.	1.0	3

#	ARTICLE	IF	CITATIONS
55	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients. Expert Opinion on Biological Therapy, 2021, 21, 97-104.	1.4	3
56	Editorial: withdrawal of anti TNFâ€alpha â€are we ready for biological therapy cycling?. Alimentary Pharmacology and Therapeutics, 2021, 54, 84-85.	1.9	3
57	Adalimumab for ulcerative colitisâ€”is the glass half empty or half full?. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 249-251.	8.2	2
58	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Digestive and Liver Disease, 2021, , .	0.4	2
59	342 Retreatment With Infliximab in Inflammatory Bowel Disease: Tolerability and Effectiveness of Different Re-Induction Regimens. Gastroenterology, 2014, 146, S-78-S-79.	0.6	1
60	Reply to Managing Patients with Ulcerative Colitis with Infliximab in Primary and Referral Gastroenterology Centers. Inflammatory Bowel Diseases, 2014, 20, E25.	0.9	0
61	The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases. Expert Opinion on Biological Therapy, 2019, 19, 967-969.	1.4	0
62	Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease. Reviews on Recent Clinical Trials, 2022, 17, 250-258.	0.4	0